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Objective:  To  compare  patient  characteristics  and  treatment  patterns  among  clobazam  (CLB)  and  clon-
azepam  (CZP)-treated  patients  with  epilepsy  in a longitudinal  primary  care  database.
Methods:  In  this  pharmacoepidemiological  study,  real-life  usage  data  from  the  Clinical  Practice  Research
Database  (CPRD)  were  evaluated.  The  CPRD  collects  data  from  approximately  690  primary  care  practices
throughout  the UK. Data  included  were  from  patients  with  ≥1  incident  CLB  or  CZP prescription  from  1995
to 2011  and  were  present  in the  database  for ≥182  days  prior  to  the  index  date  (date  patient  was  ﬁrst
prescribed  CLB  or CZP  within  the  study  period).
Results: Of  21,099  patients  who  met  inclusion  criteria,  18.4%  were receiving  CLB  and  81.6%  were  receiving
CZP.  More  patients  used  CLB  for epilepsy  than  CZP  (76.1%  vs  8.7%).  CLB-treated  adults  (≤18  years)  were
younger  than  those  treated  with  CZP  (41.0  vs  48.2  years;  p < 0.001),  while  CLB-treated  children  (≤18
years)  were  older  than those  treated  with  CZP  (8.8  vs  7.3  years,  p < 0.001).  The  median  CLB  dosage  did
not  change  from  baseline  to last  follow-up,  while  median  CZP  dosage  increased  25%  in  adults  and  50%  in
children.  Median  treatment  duration,  as  well  as  retention  rate  up to 10  years,  was  similar  between  CLB
and  CZP  in  each  age  group.
Conclusions:  Among  adult  and  pediatric  patients  in the  UK, CLB  is  more  often  prescribed  for  epilepsy  than
CZP.  The  median  CLB  dosage  used  by  both  adults  and  children  remained  stable  over the  16-year  study
period,  while  the  median  CZP  dosage  increased  in  both  adults  and  children.
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atabase; ISAC, Independent Scientiﬁc Advisory Committee; LGS, Lennox–Gastaut
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umeric daily dosage; NICE, National Institute for Health and Care Excellence.
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1. Introduction
Benzodiazepines (BZDs) have been used to treat a variety
of disorders, including anxiety, depression, insomnia, alcohol
withdrawal, and seizures. While BZDs are the most commonly
prescribed class of psychotropic medications (Olfson et al., 2015),
select few are used to treat epilepsy: diazepam and lorazepam for
seizure emergencies; midazolam for refractory status epilepticus
and seizure emergencies; nitrazepam for myoclonic seizures, infan-
tile spasms and other childhood seizures; clorazepate, clonazepam
and clobazam for long-term epilepsy management (Riss et al., 2008;
Schatzberg and Nemeroff, 2009). Though BZDs are the drugs of ﬁrst
choice for seizure emergencies (De Waele et al., 2013), their use as
maintenance treatments declined over recent decades due to con-
cerns regarding potential for abuse, tolerance, excessive sedation
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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nd cognitive decline with chronic use (Olfson et al., 2015; Paterniti
t al., 2002; Sankar et al., 2014; Stewart, 2005). The availability of
everal new antiepileptic drugs (AEDs) for maintenance therapy
lso reduced BZD use for epilepsy.
The BZDs clobazam (CLB; Onﬁ®, Deerﬁeld, IL, US) and clon-
zepam (CZP; Klonopin®, San Francisco, CA, US) have been used
orldwide since the 1970s. CZP is approved in the EU for all forms
f epilepsy and for panic attacks in adults, and in the US for panic
isorder and as mono- or adjunct therapy in a broad range of seizure
isorders, including Lennox–Gastaut syndrome (LGS). CLB has been
uccessfully used for many years in the EU as both an AED and
n anxiolytic, but was approved only recently in the US (October
011) for the adjunctive treatment of seizures associated with LGS
n patients ≥2 years (Ng et al., 2011).
As use of CLB in the EU has been well established, data from
he UK-based Clinical Practice Research Datalink were evaluated to
ompare real-world use of CLB versus CZP for epilepsy.
. Methods
.1. Data source
The Clinical Practice Research Datalink (CPRD), which fur-
hers the research developments of the General Practice Research
atabase (GPRD) (Lawson et al., 1998), comprises more than 62
illion patient-years of data collected from approximately 10
illion patients throughout the United Kingdom (UK). It is the
argest computerized database of anonymous, longitudinal, pri-
ary care clinical records. CPRD data, which are currently being
ollected from 690 primary care practices, are directly generated by
omputer from general practitioner (GP) practices equipped with
pecialized software. Data from the CPRD have been extensively
sed in over 890 clinical reviews and papers, including numer-
us pharmacoepidemiological studies. The principal information
vailable for analysis includes patient demographics, prescriptions
f medicine, clinical diagnoses, hospital or specialist referrals, and
aboratory test results (Garcia Rodriguez and Perez Gutthann, 1998;
ood and Martinez, 2004).
.2. Study design and inclusion criteria
In this historical, longitudinal, incident-user (Johnson et al.,
012) cohort study, patient data were obtained from the externally
alidated CPRD database (Jick et al., 1991; Jick et al., 2003). Epilepsy
atients who had at least one incident prescription of CLB or CZP
ithin the study period (1995–2011) were included in the analysis
Fig. 1). To ensure patients had not been previously prescribed CLB
r CZP, patient data must have been present in the database for at
east 182 days prior to the index date and without any prescription
or CLB or CZP. The index date is deﬁned as the date of ﬁrst CLB or
ZP prescription within the study period.
.3. Patient characteristics and treatment patterns evaluated
The primary objectives were to evaluate demographic charac-
eristics and treatment patterns between patients prescribed CLB
nd those prescribed CZP. Demographics and baseline characteris-
ics for patients with epilepsy included age, sex, drug dosage, and
oncomitant AED use. Patients with an epilepsy diagnosis at the
ndex date were those who had at least one record with an epilepsy
iagnosis any time prior to the index date or within 90 days follow-
ng the index date. Primary AEDs of interest were selected according
o the National Institute for Health and Care Excellence (NICE) clin-
cal guidelines regarding the management of epilepsy and grouped
ccording to the British National Formulary (BNF) classiﬁcation sys-
em.arch 123 (2016) 68–74 69
Characteristics of patients with epilepsy at follow-up included
time of follow-up, treatment duration, and drug dosage. Drug
dosage was not directly available in the database and was therefore
computed at the last prescription date using the following formula:
dosage = substance strength × numeric daily dosage (NDD), where
NDD corresponds to number of pills/tablets/milliliters per day. No
imputation was performed when NDD was  0 or missing.
The evaluation of the development of dependence was a
secondary objective of the study. Drug dependency cases were
identiﬁed by the presence of one record with a drug dependence
diagnosis (Read code: E24*—Drug dependence, Eu19211—[X]
Drug addiction NOS) or a drug dependence detoxiﬁcation (Read
code: 8BA9*—Detoxiﬁcation dependence drug) during follow-up.
Patients with a history of drug dependency before treatment initi-
ation were not included in this analysis.
2.4. Statistical analysis
Statistical comparisons between CLB- and CZP-treated groups
were performed using the student t test for continuous variables
and either the X2 or Fisher exact tests for categorical variables. For
treatment duration and analysis of drug dependence, curves were
drawn using the Kaplan-Meier method and statistical comparisons
were performed using the log-rank test. For the analysis of drug
dependence, the incidence rate per person year was  also calculated:
Incidence rate / person-year =
Number of patients with drug dependency
Total time of exposure to treatment for all patients (years)
2.5. Standard protocol approvals, registrations, and patient
consents
All research undertaken using data obtained from CPRD is
approved by, as appropriate, an ethics committee, a scientiﬁc com-
mittee, and the National Information Governance Board Ethics and
Conﬁdentiality Committee. Protocol 13 043R entitled “Treatment
Patterns in Patients With Epilepsy in Primary Care in the UK” was
approved April 3, 2013 by the Independent Scientiﬁc Advisory Com-
mittee (ISAC) for Medicines and Healthcare Products Regulatory
Agency (MHRA) Database Research for CPRD.
3. Results
3.1. CPRD patient population
Of 21,099 patients who  met  inclusion criteria, 3882 (18.4%)
received CLB and 17,217 (81.6%) received CZP (Fig. 1). Overall, CLB
was more widely used for the treatment of epilepsy than CZP as
76.1% of patients received CLB for epilepsy, while only 8.7% of
patients received CZP for epilepsy (Fig. 1).
3.2. Adult patients with epilepsy
3.2.1. Baseline characteristics
In the CPRD database, 2312 adults (≥18 years) with epilepsy
had received CLB and 1268 had received CZP (Table 1). A greater
percentage of adults with epilepsy were women, but the female-
to-male patient ratio was the same in either treatment group.
On average, CLB-treated adults were younger than those treated
with CZP (41.0 vs 48.2 years, respectively; p < 0.0001). The median
(range) CLB dose was  10.0 mg  (5.0–60.0); the median (range) CZP
dose was 0.8 mg  (3.0–8.0).
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A signiﬁcantly greater percentage of CLB-treated adults were
eceiving concomitant AEDs than those treated with CZP (93% CLB
s 79% CZP; p < 0.0001). Signiﬁcantly fewer CLB-treated adults used
oncomitant BZDs (eg, diazepam) than those receiving CZP (9% CLB
s 12% CZP; p = 0.002). The most commonly used concomitant AEDs
≥15%) among both treatment groups were carbamazepine (30%),
odium valproate (29%), lamotrigine (28%) and levetiracetam (20%).
.2.2. Follow-up characteristics
The average time of follow up for both CLB- and CZP-treated
atients was similar and greater than 5 years (5.5 years CLB vs 5.2
ears CZP; Table 2). The median CLB dosage did not change from
aseline to last follow-up, while median CZP dosage increased 25%
Tables 1 and 2). The median duration of treatment was similar
etween CLB and CZP (28.3 months CLB vs 27.5 months CZP; Fig. 2).
etention rates up to 10 years were similar between CLB- and CZP-
reated patients.
.3. Children with epilepsy
.3.1. Baseline characteristics
In the CPRD database, 574 pediatric patients (<18 years) withpilepsy had received CLB and 171 had received CZP (Table 1). A
reater percentage of children with epilepsy were males, but the
atio of male-to-female patients was the same in either treatment
roup. CLB-treated pediatric patients were older than those treated ﬂow.
with CZP (8.8 vs 7.3 years, p < 0.001). The median (range) CLB dose
was 20.0 mg  (5.0–60.0); the median (range) CZP dose was 1.0 mg
(0.3–7.5).
A comparable number of CLB- and CZP-treated children were
receiving concomitant AEDs (92% CLB vs 89% CZP; p = 0.18),
including BZDs (9% vs 10%; p = 0.73). The most commonly used con-
comitant AEDs (≥15%) in either pediatric treatment group were
sodium valproate (40%), lamotrigine (30%), carbamazepine (20%)
and topiramate (16%).
3.3.2. Follow-up characteristics
Children treated with CLB had a shorter follow-up period than
those treated with CZP (5.5 vs 6.3 years; p = 0.027). The median CLB
dosage did not increase from baseline to last follow up, while the
median CZP dosage increased 50% (Tables 1 and 2). The median
treatment duration was  similar between groups (34.6 months CLB
vs 31.2 months CZP; Fig. 3). Retention rates up to 10 years were
similar between treatment groups.
3.4. Dependence analysis for patients with epilepsy: all ages
A total of 26 CLB- and CZP-treated patients (13 in each treatment
group: 0.5% CLB, 0.9% CZP) had a conﬁrmed drug dependency diag-
nosis, indicating a 1.6 and 3.3 incidence rate (per 1000 person-year)
in the respective treatment groups. Overall, at least 11 patients
were identiﬁed as having benzodiazepine dependence, though the
M.J. Brodie et al. / Epilepsy Research 123 (2016) 68–74 71
Table  1
Demographics and baseline characteristics of patients with epilepsy receiving CLB or CZP.
Pediatric patients (<18 years) Adult patients (≥18 years)
Clobazam (n = 574) Clonazepam (n = 171) p-valuea Clobazam (n = 2312) Clonazepam (n = 1268) p-valuea
Sex Male 311 (54%) 92 (54%) 0.93 1035 (45%) 567 (45%) 0.98
Female 263 (46%) 79 (46%) 1277 (55%) 701 (55%)
Age  (years) Mean ± SD 8.8 ± 5.0 7.3 ± 5.4 <0.001 41.0 ± 14.9 48.2 ± 18.6 <0.001
Age  groups (years) 0–5 144 (25%) 72 (42%) <0.001 NA NA
6–12  261 (45%) 57 (33%) NA NA
13–17  169 (29%) 42 (25%) NA NA
18–64  NA NA 2134 (92%) 996 (79%) < 0.001
65  and older NA NA 178 (8%) 272 (21%)
Dose  (mg) Mean ± SD 18.4 ± 11.9 1.7 ± 1.6 NA 14.9 ± 7.0 1.0 ± 1.0 NA
Median 20.0 1.0 10.0 0.8
[Range] [5.0–60.0] [0.3–7.5] [5.0–60.0] [0.3–8.0]
Missing 320 (56%) 75 (44%) 1083 (47%) 445 (35%)
Any  AEDs 529 (92%) 152 (89%) 0.18 2144 (93%) 1000 (79%) < 0.001
Number  of AEDs 0 45 (8%) 19 (11%) 0.44 168 (7%) 268 (21%) <
0.0011  312 (54%) 91 (53%) 1080 (47%) 567 (45%)
2  185 (32%) 49 (29%) 808 (35%) 349 (28%)
≥3  and more 32 (6%) 12 (7%) 256 (11%) 84 (7%)
Co-prescription AEDs
Barbiturates (eg, phenobarbital) 11 (2%) 8 (5%) 0.05 68 (3%) 50 (4%) 0.11
Hydantoins (eg, phenytoin, fosphenytoin) 23 (4%) 7 (4%) 0.96 299 (13%) 181 (14%) 0.26
Succinimides (eg, ethosuximide) 20 (3%) 4 (2%) 0.46 9 (0%) 3 (0%) 0.56
Benzodiazepines (eg, CLB, CZP, diazepam) 52 (9%) 17 (10%) 0.73 206 (9%) 154 (12%) 0.002
Carboxamides (eg,
carbamazepine, oxcarbazepine,
eslicarbazepine acetate)
131 (23%) 30 (18%) 0.14 818 (35%) 313 (25%) < 0.001
Fatty  acid derivatives (eg,
valproate, tiagabine)
229 (40%) 92 (54%) 0.001 694 (30%) 391 (31%) 0.61
Others AEDs 314 (55%) 70 (41%) 0.002 1408 (61%) 441 (35%) < 0.001
CLB, clobazam; CZP, clonazepam; SD, standard deviation; NA, not applicable.
a Student t-test for continuous variables and 2 or Fisher’s exact tests for categorical variables.
Table 2
Follow-up characteristics of patients with epilepsy receiving CLB or CZP.
Pediatric patients (<18 years) Adult patients (≥18 years)
Clobazam (n = 574) Clonazepam (n = 171) p-valuea Clobazam (n = 2312) Clonazepam (n = 1268) p-valuea
Time of follow up, years (mean ± SD) 5.5 ± 3.8 6.3 ± 4.4 0.027 5.5 ± 3.9 5.2 ± 4.1 0.0023
Treatment duration, months (mean ± SD) 35.4 ± 40.6 36.8 ± 46.6 0.70 34.7 ± 42.8 32.4 ± 42.8 0.12
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LB, clobazam; CZP, clonazepam; SD, standard deviation; NA, not applicable.
a Student t-test.
articular type of BZD was not speciﬁed in the database. The likeli-
ood of patients remaining free of drug dependency over a 5-year
reatment period was 99.4% among CLB-treated patients and 98.5%
mong CZP-treated patients (Fig. 4). The incidence rate per 1000
atient Year Exposure was 1.55 among CLB-treated patients and
.29 among CZP-treated patients.
. Discussion
In addition to the treatment of anxiety and other disorders,
oth CLB and CZP have long been used in Europe for the treatment
f epilepsy, primarily idiopathic generalized and partial epilepsy.
hile concerns over safety with both acute treatment (eg, sedation,
sychomotor and cognitive impairment) and chronic use (toler-
nce, withdrawal syndrome) (Lader, 2008; Paterniti et al., 2002)
hould be considered when making treatment decisions, the ben-
ﬁts of BZDs for epilepsy appear to outweigh the risks for many
atients, including children (Conry et al., 2014; Mehndiratta et al.,
003; Montenegro et al., 2001; Silva et al., 2006).
In the longitudinal cohort study of data from the UK-based CPRD
resented here, patient characteristics and treatment patterns for
LB and CZP use from 1995 to 2011 were evaluated in both adult] NA 10.0 [5.0–60.0] 1.0 [0.3–8.0] NA
(≥18 years) and pediatric patients (<18 years). Overall, CLB was
more widely used for the treatment of epilepsy than CZP (76.1%
vs 8.7%, respectively). These results mirror the trend observed in a
previously conducted primary care cohort study that evaluated AED
utilization in the UK from 1993 to 2008 (Nicholas et al., 2012). In
that study, CLB use exceeded CZP use by the end of the study period
(CLB: 2.2% person-years in 1993–3.3% in 2008; CZP: 2.6% person-
years in 1993–2.9% in 2008), though both drugs were among the
less frequently prescribed AEDs overall (Nicholas et al., 2012).
Because of its unique 1,5 chemical structure, receptor binding
properties, and clinical effects, CLB may  offer an improved safety
proﬁle over the 1,4-BZDs, as well as sustained efﬁcacy that may
not be evident with other BZDs used to treat epilepsy (Riss et al.,
2008; Wheless and Phelps, 2013). CLB is highly selective for the
subunit of the GABAA receptor that is associated with antiepileptic
activity (2) with less afﬁnity toward the subunit that is known
to contribute to sedation (1), while CZP is nonselective for either
subunit (Jensen et al., 2014). Furthermore, though the exact manner
in which tolerance can occur with particular BZDs remains to be
determined, the differential expression of GABAA receptor subunits
in the brain and the variable afﬁnities of BZDs for those subunits
72 M.J. Brodie et al. / Epilepsy Research 123 (2016) 68–74
a Number of patients still on follow-up and for whom no events have occurred
Fig. 2. Median duration of treatment in adult patients with epilepsy.
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ca Number of patients still on follow-up and for whom no even
Fig. 3. Median duration of treatmave been implicated in the mechanisms underlying tolerance with
ZDs (Sankar, 2012; Vinkers and Olivier, 2012; Vinkers et al., 2012).
Differences in the mechanism of action between CLB and CZP
ould explain the median dosage increase observed in CZP-treated occurred
 pediatric patients with epilepsy.patients that was  not apparent in CLB-treated patients in this study.
From baseline to the follow-up period, the median CLB dosage did
not increase for either patient population, while the median CZP
dosage increased 25% in adults and 50% in children. As the initial
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osages of CLB and CZP appeared to be equivalent (10–15 mg/day
LB:1 mg/day CZP) (Sankar et al., 2014), these results suggest that
here was a therapeutic need to increase the CZP dose over time,
ossibly due to loss of efﬁcacy, and perhaps indicating the devel-
pment of tolerance to CZP that was not observed with long-term
LB use. Indeed, a loss of efﬁcacy in approximately 30% of CZP-
reated patients within 3 months of use has been suggested (Bacia
t al., 1980; Pinder et al., 1976), yet CLB use over a period of 3 years
as resulted in sustained improvements in drop- and total seizures
n patients with LGS (Conry et al., 2014). Similarly, although the
nalysis of dependence using dependence diagnosis is likely to
ack sensitivity, the higher incidence of dependence diagnosis for
ZP versus CLB further supports a possible difference in tolerance
roﬁle between the drugs. A difference in tolerance between CLB
nd CZP treatment can have important clinical implications: CZP
ay  be more appropriate for shorter-term use for non–epilepsy-
elated disorders, while clobazam may  be considered an effective,
ong-term therapy for various forms of epilepsy.
Overall, CLB-treated adults in this study were receiving more
oncomitant AEDs than CZP-treated adults, an observation that
ay be attributed to the fact that CLB is primarily used as an adjunc-
ive epilepsy therapy in the UK. A less likely explanation is that such
ifferences in AED usage might indicate greater disease severity
mong those in the CLB group or possibly reﬂect variable use of
hese two BZDs for different types of epilepsy; such conclusions
annot be made without additional patient information and analy-
es. Though the CPRD database is broadly representative of the UK
opulation, there are some inherent limitations of this database
ncluding the possibility of missing data (which may  be due to the
nability to capture prescriptions from neurologists), a lack of con-
ideration for confounding effects, and the inability to identify the
ype of epilepsy for which patients are receiving either CLB or CZP.
The median treatment duration was similar between CLB- and
ZP-treated groups in both adult and pediatric populations, but
he follow-up period was slightly shorter for CLB-treated children
ompared to their CZP-treated counterparts (5.5 vs 6.3 years). The
eason for the slight variation in length of follow-up among the
LB- and CZP-treated pediatric population is unclear, as is the cause
or the opposing pattern of CLB vs CZP use by age: adult patients
reated with CLB for epilepsy were younger than those treated with
ZP, while CLB-treated children were older than their CZP-treated
ounterparts. These results may  simply reﬂect variability in patient
are among the physicians in the UK who issue the majority of long-
erm prescriptions and manage the continuity of AED treatments.Time to Drug Dependency.
5. Future directions
Further analysis of the CPRD database supplemented with data
from a managed care database could include comparisons of AED
effectiveness through an evaluation of surrogates for effectiveness,
such as rates of hospitalizations, in-patient and out-patient ofﬁce
visits, as well as changes in AED prescriptions (dosage changes,
newly added medications).
6. Conclusions
In the UK, stable doses of CLB have been used for
years—primarily for the treatment of epilepsy in both adult and
pediatric patients—while CZP use in epilepsy is limited. An increase
in the median dose of CZP used was  evident in the 16-year study
period, but no such dose increase was observed in patients treated
with CLB. The results from this study suggest that UK physicians
prefer CLB over CZP for the treatment of epilepsy.
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